

Theresa Falls

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/476536/theresa-falls-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

45
papers

2,904
citations

29
h-index

45
g-index

45
ext. papers

3,305
ext. citations

10.8
avg, IF

4.14
L-index

#	Paper	IF	Citations
45	Different ODE models of tumor growth can deliver similar results. <i>BMC Cancer</i> , 2020 , 20, 226	4.8	2
44	In vivo characterization of [F]AVT-011 as a radiotracer for PET imaging of multidrug resistance. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 2026-2035	8.8	0
43	Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	164
42	Tudor Domain Containing Protein 3 Promotes Tumorigenesis and Invasive Capacity of Breast Cancer Cells. <i>Scientific Reports</i> , 2017 , 7, 5153	4.9	8
41	Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 221-227	8.9	17
40	Expression of the fusogenic p14 FAST protein from a replication-defective adenovirus vector does not provide a therapeutic benefit in an immunocompetent mouse model of cancer. <i>Cancer Gene Therapy</i> , 2016 , 23, 355-364	5.4	7
39	Adenovirus-Mediated Expression of the p14 Fusion-Associated Small Transmembrane Protein Promotes Cancer Cell Fusion and Apoptosis In Vitro but Does Not Provide Therapeutic Efficacy in a Xenograft Mouse Model of Cancer. <i>PLoS ONE</i> , 2016 , 11, e0151516	3.7	7
38	Oncolytic vesicular stomatitis virus expressing interferon- β has enhanced therapeutic activity. <i>Molecular Therapy - Oncolytics</i> , 2016 , 3, 16001	6.4	46
37	Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. <i>Molecular Therapy - Oncolytics</i> , 2016 , 3, 16027	6.4	9
36	Murine Tumor Models for Oncolytic Rhabdo-Virotherapy. <i>ILAR Journal</i> , 2016 , 57, 73-85	1.7	8
35	Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment. <i>Breast Cancer Research</i> , 2016 , 18, 83	8.3	53
34	VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. <i>Cancer Cell</i> , 2015 , 28, 210-24	24.3	62
33	Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. <i>Nature Communications</i> , 2015 , 6, 6410	17.4	36
32	Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. <i>Molecular Therapy</i> , 2015 , 23, 1066-1076	11.7	54
31	Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. <i>Nature Medicine</i> , 2015 , 21, 530-6	50.5	93
30	Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model. <i>Gene Therapy</i> , 2015 , 22, 65-75	4	25
29	Programmable insect cell carriers for systemic delivery of integrated cancer biotherapy. <i>Journal of Controlled Release</i> , 2015 , 220, 210-221	11.7	10

28	Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression. <i>Oncotarget</i> , 2015 , 6, 3013-32	3.3	57
27	Double-stranded RNA-dependent protein kinase deficiency protects the heart from systolic overload-induced congestive heart failure. <i>Circulation</i> , 2014 , 129, 1397-406	16.7	35
26	Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy. <i>Molecular Therapy</i> , 2014 , 22, 1188-1197	11.7	27
25	Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease. <i>Molecular Therapy</i> , 2014 , 22, 1320-1332	11.7	43
24	Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency. <i>Cancer Research</i> , 2014 , 74, 3567-78	10.1	69
23	Oncolytic Vaccinia virus safely and effectively treats skin tumors in mouse models of xeroderma pigmentosum. <i>International Journal of Cancer</i> , 2013 , 132, 726-31	7.5	10
22	Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma. <i>Journal of Virology</i> , 2013 , 87, 2363-6	6.6	15
21	Model-based rational design of an oncolytic virus with improved therapeutic potential. <i>Nature Communications</i> , 2013 , 4, 1974	17.4	35
20	Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. <i>Cancer Research</i> , 2013 , 73, 97-107	10.1	133
19	Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity. <i>Blood Cancer Journal</i> , 2013 , 3, e123	7	14
18	Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia. <i>Clinical Cancer Research</i> , 2013 , 19, 3832-43	12.9	23
17	Surgical stress promotes the development of cancer metastases by a coagulation-dependent mechanism involving natural killer cells in a murine model. <i>Annals of Surgery</i> , 2013 , 258, 158-68	7.8	60
16	Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. <i>Molecular Therapy</i> , 2012 , 20, 1791-9	11.7	56
15	ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic. <i>Molecular Therapy</i> , 2012 , 20, 1148-57	11.7	36
14	The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. <i>Molecular Therapy</i> , 2012 , 20, 749-58	11.7	177
13	Targeting tumor vasculature with an oncolytic virus. <i>Molecular Therapy</i> , 2011 , 19, 886-94	11.7	122
12	Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. <i>Cancer Cell</i> , 2011 , 20, 443-56	24.3	82
11	Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. <i>Molecular Therapy</i> , 2011 , 19, 1170-9	11.7	103

10	Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. <i>Molecular Therapy</i> , 2010 , 18, 896-902	11.7	25
9	Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. <i>Molecular Therapy</i> , 2010 , 18, 1440-9	11.7	105
8	A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. <i>Molecular Therapy</i> , 2010 , 18, 1123-9	11.7	67
7	Synergistic interaction between oncolytic viruses augments tumor killing. <i>Molecular Therapy</i> , 2010 , 18, 888-95	11.7	97
6	Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. <i>PLoS ONE</i> , 2010 , 5, e14462	3.7	54
5	A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. <i>Molecular Therapy</i> , 2008 , 16, 1437-43	11.7	108
4	Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 14981-6	11.5	146
3	Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. <i>Molecular Therapy</i> , 2007 , 15, 1686-93	11.7	210
2	Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. <i>Molecular Therapy</i> , 2007 , 15, 123-30	11.7	152
1	Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress. <i>Molecular and Cellular Biology</i> , 2006 , 26, 9517-32	4.8	242